Holen Sie sich die Stockscreener-App
38.27
0.39%
-0.15
Schlusskurs vom Vortag:
$38.42
Offen:
$38.44
24-Stunden-Volumen:
1.23M
Relative Volume:
0.55
Marktkapitalisierung:
$7.13B
Einnahmen:
$29.52M
Nettoeinkommen (Verlust:
$-567.06M
KGV:
-10.46
EPS:
-3.66
Netto-Cashflow:
$-551.11M
1W Leistung:
+1.22%
1M Leistung:
-3.50%
6M Leistung:
-6.48%
1J Leistung:
-20.17%
1-Tages-Spanne:
$38.06
$39.25
1-Wochen-Bereich:
$38.06
$39.62
52-Wochen-Spanne:
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
Firmenname
Revolution Medicines Inc
Sektor
Branche
Telefon
415-766-3638
Adresse
700 SAGINAW DR, REDWOOD CITY, CA
Vergleichen Sie RVMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
38.27 | 7.04B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2024-07-16 | Bestätigt | Needham | Buy |
| 2024-07-12 | Eingeleitet | Barclays | Overweight |
| 2024-07-08 | Eingeleitet | Jefferies | Buy |
| 2024-04-12 | Bestätigt | Needham | Buy |
| 2024-04-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-01-04 | Eingeleitet | Wedbush | Outperform |
| 2023-11-16 | Eingeleitet | Raymond James | Outperform |
| 2023-02-28 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-12-14 | Eingeleitet | Needham | Buy |
| 2022-10-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-05-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-03-01 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-23 | Eingeleitet | Stifel | Hold |
| 2021-08-12 | Herabstufung | Goldman | Buy → Neutral |
| 2021-05-18 | Eingeleitet | Goldman | Buy |
| 2020-05-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-03-09 | Eingeleitet | Cowen | Outperform |
| 2020-03-09 | Eingeleitet | Guggenheim | Buy |
| 2020-03-09 | Eingeleitet | JP Morgan | Neutral |
Alle ansehen
Revolution Medicines Inc Aktie (RVMD) Neueste Nachrichten
How will RVMD's EPS trend in Q1 2025? - AInvest
What analysts say about Revolution Medicines Inc. stockFree Bull & Bear Market Updates - jammulinksnews.com
Revolution Medicines Inc. Equity Warrant Stock Analysis and ForecastOutperformance with explosive growth - jammulinksnews.com
What drives Revolution Medicines Inc. stock priceConsistently high returns - jammulinksnews.com
What drives Revolution Medicines Inc. Equity Warrant stock pricePhenomenal trading returns - jammulinksnews.com
Is Revolution Medicines Inc. a good long term investmentRapid return acceleration - jammulinksnews.com
Revolution Medicines Inc. Stock Analysis and ForecastRapidly growing investment returns - jammulinksnews.com
What analysts say about Revolution Medicines Inc. Equity Warrant stockExceptional risk-adjusted gains - Autocar Professional
Is Revolution Medicines Inc. Equity Warrant a good long term investmentSky-high profits - Autocar Professional
(RVMD) On The My Stocks Page - news.stocktradersdaily.com
Revolution Medicines (RVMD) Gets Initiated With a New Buy Rating at Goldman Sachs - MSN
What makes Revolution Medicines Inc. Equity Warrant stock price move sharplyInvestor Friendly Risk Reward - beatles.ru
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors - MSN
Revolution Medicines’ Daraxonrasib Granted FDA Breakthrough Therapy Designation for Pancreatic Cancer with KRAS G12 Mutations - MSN
Revolution Meds partners with AI specialist Iambic - The Pharma Letter
Revolution Medicines partners with Iambic for AI-driven drug discovery By Investing.com - Investing.com South Africa
Revolution Medicines, Inc. and Iambic Therapeutics Announce Technology and Research Collaboration Using Iambic's Ai Discovery Tools to Pursue New Drug Candidates - MarketScreener
Revolution Medicines, Iambic Therapeutics Form AI-Powered Drug Discovery Partnership - MarketScreener
Revolution Medicines partners with Iambic for AI-driven drug discovery - Investing.com
Revolution Medicines And Iambic Therapeutics Partner To Develop Novel Drug Candidates Using AI Models In Multi-Year Collaboration; Iambic To Receive Up To $25M Through A Combination Of Upfront And Expected Near-Term Performance-Based Milesto - 富途牛牛
Revolution Medicines and Iambic Therapeutics Announce Collaboration to Explore Novel Drug Candidates Using Advanced AI Models - Quiver Quantitative
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates - The Manila Times
Revolution Medicines and Iambic Announce Technology and - GlobeNewswire
Revolution Medicines Taps Iambic's AI Platform in $25M Deal to Accelerate Cancer Drug Discovery - Stock Titan
Revolution Medicines and Iambic Therapeutics: AI-Powered Oncology Breakthroughs Drive Investment Upside - AInvest
Finanzdaten der Revolution Medicines Inc-Aktie (RVMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):